Immunology · Year 2 · from Immunology

Case 2: CAR-T Cell Therapy with Cytokine Release Syndrome

Patient Presentation

Demographics: 34-year-old male

Chief Complaint: Fever and confusion 5 days after CAR-T infusion

History of Present Illness: The patient has relapsed/refractory diffuse large B-cell lymphoma (DLBCL) after 3 prior lines of therapy. He received axicabtagene ciloleucel (CD19-targeted CAR-T cells) 5 days ago. He developed fever (39.5C) on day 3 post-infusion with progressive hypotension, now requiring vasopressors. Today he is confused and disoriented.

Past Medical History:

  • DLBCL diagnosed 2 years ago
  • Relapsed after R-CHOP, salvage chemotherapy, and autologous transplant
  • No other significant medical history

Physical Examination:

  • Blood pressure: 82/50 mmHg (on norepinephrine)
  • Heart rate: 118 bpm
  • Temperature: 40.1C
  • Oxygen saturation: 92% on 4L nasal cannula
  • General: Ill-appearing, confused
  • Lungs: Bibasilar crackles
  • Neurologic: Oriented only to self, mild tremor

Workup and Results

Laboratory Studies:

  • WBC: 1,200/mcL (pancytopenic from lymphodepletion)
  • Hemoglobin: 8.4 g/dL
  • Platelets: 42,000/mcL
  • Ferritin: 18,500 ng/mL (markedly elevated)
  • CRP: 285 mg/L (markedly elevated)
  • IL-6: 2,840 pg/mL (markedly elevated)
  • Fibrinogen: 98 mg/dL (low - DIC concern)
  • LDH: 1,250 U/L

Imaging:

  • CT head: No acute abnormality
  • Chest X-ray: Bilateral pulmonary infiltrates

Clinical Image

Diagram illustrating cytokine release syndrome (CRS) pathophysiology following CAR-T cell activation. Massive cytokine release, particularly IL-6, leads to systemic inflammatory response with fever, hypotension, capillary leak, and multi-organ dysfunction.

Diagnosis

Grade 4 Cytokine Release Syndrome (CRS) with Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

CRS Grade 4 criteria met:

  • Fever >38C
  • Hypotension requiring vasopressors
  • Hypoxia requiring supplemental oxygen

ICANS features:

  • Confusion/encephalopathy

Discussion

This case demonstrates CAR-T complications:

  • CRS Mechanism: The lecture describes how CRS results from massive cytokine production when activated CAR-T cells encounter target antigen. IL-6 is the key driver, produced by monocytes/macrophages activated by CAR-T cells.
  • IL-6 as Key Cytokine: The lecture identifies IL-6 as the key cytokine in CRS pathophysiology. Elevated ferritin and CRP are characteristic markers.
  • ICANS: The lecture explains that ICANS (neurotoxicity) presents with confusion, tremor, word-finding difficulty, and can progress to seizures. It may occur with or after CRS.
  • Tocilizumab First-Line: The lecture states that tocilizumab (anti-IL-6 receptor) is first-line for CRS because it rapidly reverses cytokine-mediated inflammation without impairing CAR-T cell efficacy against tumor.

Treatment Plan

  1. CRS Treatment:
  • Tocilizumab 8 mg/kg IV (can repeat in 8 hours if needed)
  • Continue vasopressors
  • Supportive care: IV fluids, oxygen
  1. ICANS Treatment:
  • Dexamethasone 10 mg IV every 6 hours
  • Corticosteroids are preferred for neurotoxicity (tocilizumab doesn't cross BBB well)
  • Seizure prophylaxis (levetiracetam)
  1. Monitoring:
  • ICU level care
  • Serial neurologic assessments
  • Daily CRP, ferritin, IL-6
  1. Supportive Care:
  • Blood product support as needed
  • Broad-spectrum antibiotics (infectious workup, though CRS most likely)
  1. Expected Course:
  • Most CRS resolves within 1-2 weeks
  • Response assessment at day 28-30

Teaching Points

  1. CRS is driven by massive cytokine release, particularly IL-6
  2. Tocilizumab (anti-IL-6R) is first-line for CRS
  3. ICANS is treated with corticosteroids (tocilizumab less effective)
  4. Elevated ferritin and CRP are characteristic CRS markers
  5. B-cell aplasia is an expected "on-target, off-tumor" effect of CD19 CAR-T

All cases for this lecture as Markdown